Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Dermatophytic Onychomycosis Treatment Companies

ID: MRFR/HC/10012-HCR
128 Pages
Vikita Thakur
Last Updated: February 16, 2025
Addressing fungal nail infections, Dermatophytic Onychomycosis Treatment companies specialize in developing effective therapies. Through research and innovation, they offer treatments that combat dermatophytes, providing patients with solutions to manage and eradicate onychomycosis, promoting healthier nails and improved quality of life.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Dermatophytic Onychomycosis Treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.9%
2024 Market Size$ 4.96 Billion
2025 Market Size$ 5.36 Billion
2035 Market Size$ 11.46 Billion
Key Players
Bristol-Myers Squibb
Novartis
Pfizer
Bayer
Galderma
Sanofi
Opportunities
  • Rising Healthcare Expenditure
  • Increased Focus on Preventive Healthcare
  • Growing Demand for Over-the-Counter Treatments

Top Industry Leaders in the Dermatophytic Onychomycosis Treatment Market

Dermatophytic Onychomycosis Treatment Key Companies
 
Latest Dermatophytic Onychomycosis Treatment Companies Update:

Alembic Pharmaceuticals Limited: In April 2023, Alembic received tentative FDA approval for its Efinaconazole Topical Solution, a new antifungal treatment for onychomycosis. This could significantly expand their market reach.

Lucira Therapeutics: In December 2023, Lucira announced positive Phase 3 trial results for its LCLX-101, a novel topical antifungal treatment for onychomycosis. This could potentially usher in a new class of treatments.

Bausch Health Companies Inc.: In September 2023, Bausch Health announced a partnership with Pfizer to develop and commercialize a new oral antifungal medication for onychomycosis. This collaboration combines expertise from two major players in the market.

Galderma: In July 2023, Galderma launched a new topical antifungal cream for onychomycosis, Kerydin MAX. This new formulation offers improved efficacy and patient comfort.

List of Dermatophytic Onychomycosis Treatment Key companies in the market
  • Bausch Health Companies Inc.
  • Pfizer Inc.
  • Galderma
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Cipla Inc.
  • Kaken pharmaceuticals Co., Ltd.